

#### Clinical & Translational Research Outputs: An Introduction to the Translational Sciences Benefits Model (TSBM)

CU-CSU Summit

August 16, 2023

#### AMY HUEBSCHMANN, MD, MSc

Associate Professor, Clinician-Investigator, Division of General Internal Medicine

Co-Director, Capacity Building Working Group for the NIH-funded Implementation Science Centers for Cancer Control and Prevention (ISC<sub>3</sub>)

Director, National Resource Core, Center for American Indian and Alaskan Native Health Diabetes Translation Research


Lead Scientist, Community Education, and Outreach, University of Colorado Ludeman Family Center for Women's Health Research

### Objectives

- Understand ways to demonstrate real-world impact of research with the Translational Sciences Benefits Model (TSBM)
- Recognize the available toolkits to help apply the TSBM to research projects
- Identify the role of implementation outcomes as translational outcomes that are upstream of TSBM outputs

#### How do we measure research impact?

- Publications
  - High-quality journals
  - Citations by others
- Grant funding



#### How do we measure research impact?

- Publications
  - High-quality journals
  - Citations by others
- Grant funding



Problem: How do we quantify the real-world impact of our research?

#### How do we measure research impact?

- Publications
  - High-quality journals
  - Citations by others
- Grant funding

Citation: Clin Transl Sci (2018) 11, 77–84; doi:10.1111/cts.12495 © 2017 ASCPT. All rights reserved

#### Solution?


ARTICLE

#### The Translational Science Benefits Model: A New Framework for Assessing the Health and Societal Benefits of Clinical and Translational Sciences

Douglas A. Luke<sup>1,\*</sup>, Cathy C. Sarli<sup>2</sup>, Amy M. Suiter<sup>2</sup>, Bobbi J. Carothers<sup>1</sup>, Todd B. Combs<sup>1</sup>, Jae L. Allen<sup>3</sup>, Courtney E. Beers<sup>3</sup> and Bradley A. Evanoff<sup>4</sup>

#### Classic TSBM

<u>Translational Science Benefits Model</u>: a framework that public health and clinical scientists can use to demonstrate the impact of their work in the real world



### **Overview of TSBM outputs**



New clinical innovations: tools, guidelines and/or procedures

#### OR

Improved adoption and/or implementation in clinical settings



New community innovations: activities and/or products

#### OR

Improved adoption and/or implementation enhances healthcare delivery and/or community well-being



Economic

New commercial product innovations

OR

Improved financial savings/benefits



Involvement with the policy process

OR

Formal adoption of innovations into policies, legislation or governmental standards

### Examples of TSBM outputs



# Procedures & guidelines

- Diagnostic procedures
- Therapeutic procedures
- Guidelines

#### Tools & products

- Biomedical technology
- Pharmaceuticals
- Software technologies



# Health activities & products

- Consumer software
- Health education resources

# Health care characteristics

- Accessibility
- Quality

#### Health promotion

- Disease prevention
- Quality of life



# Commercial products

- License agreements
- Non-profit or commercial entities
- Patents

# Financial savings & benefits

- Cost effectiveness
- Cost savings
- Societal & financial cost of illness




#### Advisory activities

- Committee participation
- Expert testimony
- Scientific research reports

Policies & legislation

- Legislation
- Policies
- Standards

#### How can I use the TSBM for my work?



# Toolkit to show TSBM impact

<u>Tools - Translational Science Benefits</u> <u>Model (wustl.edu)</u>

#### TRANSLATING FOR IMPACT TOOLKIT SCHEMATIC



Review, revisit & retrieve information from tools in earlier steps


# Toolkit to show TSBM impact

<u>Tools - Translational Science Benefits</u> <u>Model (wustl.edu)</u>

## TRANSLATING FOR IMPACT TOOLKIT SCHEMATIC TRANSLATING for IMPACT

A toolkit to help you plan, track & demonstrate the societal & health benefits of your research

000



Review, revisit & retrieve information from tools in earlier steps

# Example TSBM "Case Study": Proyecto




#### Improving Childhood Cancer Outcomes in Latin America

By <u>ICTS</u> and <u>St. Jude Global</u> July 27, 2023

Proyecto EVAT: A multicenter implementation of pediatric early warning scores (PEWS) in resourcelimited settings

Improving Childhood Cancer Outcomes in Latin America – Translational Science Benefits Model (wustl.edu)

# Example TSBM "Case Study": Proyecto EVAT



Proyecto EVAT implemented EVAT PEWS in 80 medical centers across 20 countries throughout Latin America

### Proyecto EVAT "Case Study"

#### **Benefits**

*Demonstrated* benefits are those that have been observed and are verifiable. *Potential* benefits are those logically expected with moderate to high confidence.

EVAT PEWS is a diagnostic system to predict deteriorating health in hospitalized pediatric cancer patients.<sup>15</sup> *Demonstrated.* 



#### Diagnostic procedures

EVAT PEWS was implemented in 80 low-resource hospitals, allowing for earlier detection of deteriorating health in hospitalized children who would not otherwise have access to such care. *Demonstrated.* 



Health care accessibility

### Proyecto EVAT "Case Study"

Implementing EVAT PEWS resulted in yearly savings of up to 350,000 dollars.<sup>12</sup> *Demonstrated.* 

By improving pediatric cancer outcomes, Proyecto EVAT could reduce the substantial economic cost of pediatric cancer on low- and middle-income countries. *Potential.* 

The Instituto Mexicano del Seguro Social, a public health system in Mexico, is integrating EVAT PEWS into their national health policies. *Potential.* 





Policies

#### Problems with TSBM

Identifying TSBM outputs during a 1-year or 5-year grant cycle is often difficult

NIH institutes are increasingly requesting reports on TSBM outputs from grantees

- National Cancer Institute (NCI)
  - Reporting on TSBM requested of Implementation Science Centers for Cancer Control and Prevention (ISC3) - 2022
- National Institute for Digestive, Diabetes, and Kidney Diseases (NIDDK)
  - Annual reporting on TSBM requested for Centers for Diabetes Translational Research – beginning in 2023


#### How to address this?


Use the TSBM toolkit

Begin with the end in mind – consider up-front the TSBM outputs you want to assess

Consider both:

- Demonstrated impact
- Potential impact






Review, revisit & retrieve information from tools in earlier steps

#### How to address this?




Include reporting on the **upstream Translational Science Outcomes** that predict potential downstream TSBM impact



#### Revised TSBM



The ISC<sub>3</sub> alliance updated the classic TSBM framework to add implementation science outcomes to the other dimensions of benefit that public health and clinical scientists can use to demonstrate the impact of their work



# What are Implementation Science outcomes?

## Examples of Implementation Science outcomes

REACH Proportion of the target population that participated in the programme



EFFICACY Success rate defined by positive outcomes minus negative outcomes

ADOPTION Proportion of settings that plan to adopt the programme



IMPLEMENTATION Extent to which the programme is implemented as intended





R

Α


MAINTENANCE Extent to which a programme is sustained over time





## **Examples of Implementation Science**

#### outcomes



E. Proctor et al., Outcomes for Implementation research, 2011

UNIVERSITY OF COLORADO GRADUATE CERTIFICATE FOR D&I SCIENCE (2019-PRESENT)

#### **OVERVIEW**

The mission of the D&I Graduate Certificate Program is to equip our graduates with the D&I research skills needed to design rigorous and innovative translational research, and to successfully compete for federal funding to carry out their proposed work.

Small class size & synchronously meet online

12 credits completed over ~2-3 years

Courses mapped to core D&I competencies (Padek et al., Impl Sci, 2015; Tabak et al., Am J Prev Med, 2017)

#### Impact to date

- International **Reach**: 51 scholars from USA and Canada enrolled since 2019; 15 graduates
- Building partnerships across ISC3 centers and NIH
  - Includes guest lecturers from these organizations:
    - National Cancer Institute
    - Harvard ISC3
    - Penn ISC<sub>3</sub> guest lecture
    - Washington University in St. Louis ISC3
- Multi-center partnerships for research/training led by Certificate students/faculty
  - Example: University of Minnesota trainee (Monden) and CU faculty (Studts) led a D&I Capacity-building workshop for Physical Medicine & Rehab researchers







• Scholars represent multiple agencies and universities across the United States and Canada: see map


Specific agencies and universities represented by students enrolled to date:

AltaMed, Centers for Disease Control and Prevention's National Institute for Occupational Safety and Health, Cincinnati Rainbow Children's Hospital, Cleveland Clinic, Colorado School of Public Health, Colorado State University, Eastern Colorado Veterans Administration Medical Center, Kaiser Permanente Colorado, Northwell Health, University of Colorado, University of Minnesota, University of Montreal, University of New Mexico, University of North Carolina Chapel Hill, and Weill-Cornell

#### SUMMARY

### TSBM HELPS DEMONSTRATE THE REAL-WORLD IMPACT OF A PROJECT

- Four classic TSBM outputs:
  - Clinical
  - Community
  - Economic
  - Policy
- Assessing implementation outcomes are additional nearterm ways to demonstrate project impact



THANK YOU

AMY HUEBSCHMANN, MD, MSC Amy.Huebschmann@cuanschutz.edu @ahuebschmann

Acknowledgement for slide development to our COISC<sub>3</sub> team members (PI, Russ Glasgow, PhD, project manager – Bryan Ford, and co-investigator Monica Perez Jolles, PhD, and partners at Washington University ISC<sub>3</sub> (Ross Brownson and colleagues)